Cellectis
CLLS
#9601
Rank
A$0.17 B
Marketcap
A$1.70
Share price
-6.35%
Change (1 day)
-75.08%
Change (1 year)

Earnings for Cellectis (CLLS)

Earnings in 2026 (TTM): -A$96.17 Million

According to Cellectis's latest financial reports the company's current earnings are A$56.57 Million. In 2025 the company made an earning of -A$97.72 Million a decrease over its 2024 earnings that were of -A$52.81 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Cellectis from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -A$96.17 Million-1.59%
2025 -A$97.72 Million85.03%
2024 -A$52.81 Million-73.42%
2023 -A$0.2 Billion60.8%
2022 -A$0.13 Billion-31.26%
2021 -A$0.18 Billion27.21%
2020 -A$0.15 Billion-14.62%
2019 -A$0.17 Billion30.34%
2018 -A$0.13 Billion-15.03%
2017 -A$0.15 Billion62.18%
2016 -A$92.13 Million185.48%
2015 -A$32.27 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Regeneron Pharmaceuticals
REGN
A$7.42 B-7,967.20%๐Ÿ‡บ๐Ÿ‡ธ USA
uniQure
QURE
-A$0.36 Billion 273.36%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
-A$0.33 Billion 240.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
-A$0.12 Billion 20.90%๐Ÿ‡บ๐Ÿ‡ธ USA